



## Nyrada Extraordinary General Meeting Results

**Sydney, 16 June 2021:** Nyrada Inc (ASX: NYR), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases today announces the results of today's Extraordinary General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

***All resolutions were passed and decided by way of a poll.***

- ENDS -

### About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.*

#### **Investor & Corporate Enquiries:**

Laura Vize  
Investor Relations Manager  
T: 0417 026 056  
E: [info@nyrada.com](mailto:info@nyrada.com)

#### **Company Secretary:**

David Franks  
T: 02 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

#### **Media Enquiries:**

Catherine Strong  
Citadel-MAGNUS  
T: 02 8234 0111  
E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)



## **Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

# Disclosure of Proxy Votes

## Nyrada Inc

Extraordinary General Meeting 2021

Wednesday, 16 June 2021



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Ratification of Prior Issue of Tranche 1 CDIs under ASX Listing Rule 7.1	P	47,224,408	47,059,541 99.65%	63,717 0.13%	43,950	101,150 0.21%	47,349,939 99.87%	63,717 0.13%	43,950
2 Ratification of Prior Issue of Tranche 1 CDIs under ASX Listing Rule 7.1A	P	48,340,007	48,175,140 99.66%	63,717 0.13%	43,950	101,150 0.21%	48,465,538 99.87%	63,717 0.13%	43,950
3 Approval of Issue of Tranche 2 CDIs	P	46,842,920	46,678,053 99.65%	63,717 0.14%	43,950	101,150 0.22%	46,968,451 99.86%	63,717 0.14%	43,950
4 Approval of Issue of Broker CDIs	P	48,619,966	48,450,437 99.65%	68,379 0.14%	43,423	101,150 0.21%	48,740,835 99.86%	68,379 0.14%	43,423
5 Approval of Issue of Management and Other CDIs	P	49,320,316	49,130,787 99.62%	88,379 0.18%	43,423	101,150 0.21%	49,356,185 99.82%	88,379 0.18%	108,423
6 Approval of Issue of Broker Options	P	48,619,966	48,430,437 99.61%	88,379 0.18%	43,423	101,150 0.21%	48,720,835 99.82%	88,379 0.18%	43,423
7 Approval of Issue of Advisor Options	P	48,614,966	48,425,437 99.61%	88,379 0.18%	48,423	101,150 0.21%	48,715,835 99.82%	88,379 0.18%	48,423



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Approval of Issue of Advisor Options	P	48,614,966	48,425,437 99.61%	88,379 0.18%	48,423	101,150 0.21%	48,715,835 99.82%	88,379 0.18%	48,423
9 Approval of Issue of CDIs to John Moore, Chairman and Director of the Company	P	49,121,616	48,915,622 99.58%	104,844 0.21%	242,123	101,150 0.21%	49,206,020 99.79%	104,844 0.21%	242,123
10 Approval of Issue of CDIs to Christopher Cox, Director of the Company	P	49,284,116	48,278,122 97.96%	104,844 0.21%	79,623	901,150 1.83%	48,568,520 99.78%	104,844 0.22%	79,623
11 Approval of Issue of CDIs to Dr Ian Dixon, Director of the Company	P	39,393,591	39,187,597 99.48%	104,844 0.27%	9,970,148	101,150 0.26%	39,477,995 99.74%	104,844 0.26%	9,970,148
12 Approval of Issue of CDIs to Dr Ruediger Weseloh, Director of the Company	P	49,279,746	49,073,752 99.58%	104,844 0.21%	83,993	101,150 0.21%	49,364,150 99.79%	104,844 0.21%	83,993
13 Approval of Issue of CDIs to Marcus Frampton, Director of the Company	P	49,284,116	48,968,047 99.36%	104,844 0.21%	79,623	211,225 0.43%	49,258,445 99.79%	104,844 0.21%	79,623
14 Approval of Issue of CDIs to Peter Marks, Director of the Company	P	49,234,116	48,327,772 98.16%	805,194 1.64%	129,623	101,150 0.21%	48,618,170 98.37%	805,194 1.63%	129,623

